Summary
Whether and to what extent activation of peripheral presynaptic dopamine2-receptors may modulate the release of norepinephrine (NE) and so affect blood pressure (BP) in normal or hypertensive man is not clear. The hydrogenated ergotoxine derivative, co-dergocrine, given in effective antihypertensive rather than excessive experimental doses, has recently been shown to act predominantly as a peripheral dopamine2-receptor agonist in several species. Accordingly, BP regulation assessed has been in 8 normal men on placebo and after 3 weeks on co-dergocrine 4 mg/day. Co-dergocrine significantly reduced urinary NE excretion from 43 to 33 µg/24 h, supine and upright plasma NE 21 to 16 and 49 to 36 ng/dl, respectively, heart rate (−8 and −5%, respectively) and upright systolic BP, 115 to 102 mm Hg; upright diastolic BP also tended to be lower. A standard pressor dose of infused NE was lowered from 131 to 102 ng/kg/min, and the relationship between NE-induced changes in BP and concomitant NE infusion rate or plasma NE concentration was displaced to the left. Exchangeable sodium and plasma volume tended to be slightly decreased. Plasma and urinary electrolytes and epinephrine, plasma renin activity and aldosterone levels, pressor responsiveness to angiotensin II, the chronotropic responses to isoproterenol, and the NE-induced rise in BP, plasma clearance of NE, glomerular filtration rate and effective renal plasma flow were not consistently modified. The findings are consistent with effective peripheral dopamine2-receptor agonism by co-dergocrine in humans. Peripheral presynaptic dopaminergic activation may modulate sympathetic activity and BP in normal man.
Similar content being viewed by others
References
Langer SZ (1981) Presynaptic regulation of the release of catecholamines. Pharmacol Rev 32: 337–362
Taylor AA, Fennell WH, Feldman MB, Brandon TA, Ginos JZ, Mitchell JR (1983) Activation of peripheral dopamine presynaptic receptors lowers blood pressure and heart rate in dogs. Hypertension 5: 226–234
Clark BJ, Bucher T, Waite R (1984) Pharmacological analysis of the cardiovascular effects of co-dergocrine (Hydergine). In: Bergener M, Grobecker H (eds) Hypertonie im Alter — Normvariante oder Krankheit? Schattauer, Stuttgart New York, pp 155–165
Bock KD, Welzel D, Dennler NJ (1982) Co-dergocrinmesylat bei älteren Hypertonikern. Münch Med Wochenschr 124: 1095–1098
Krönig B, Dennler H-J (1984) Behandlung des älteren Hochdruckkranken mit Co-dergocrinmesylat. Therapiewoche 34: 4887–4900
Weidmann P, Beretta-Piccoli C, Ziegler WH, Keusch G, Glück Z (1978) Age versus urinary sodium for judging renin, aldosterone and catecholamine levels. Studies in normal subjects and patients with essential hypertension. Kidney Int 14: 619–628
Sörgel F, Abisch E, Dennler HJ, Lang E (1984) Steady state bioavailability of a new oral formulation of Hydergine in geriatric patients. Eur J Clin Pharmacol 26: 133–135
Weidmann P, de Chatel R, Ziegler WH, Flammer J, Reubi FC (1978) Alpha- and beta-adrenergic blockade with orally administered labetalol in hypertension. Studies on blood volume, plasma renin and aldosterone and catecholamine excretion. Am J Cardiol 41: 570–576
Reubi FC (1963) Clearance tests in clinical medicine. CC Thomas, Springfield, Illinois
Vorburger C, Riedwyl H, Reubi FC (1969) Vergleichende Studien zwischen den renalen Clearances von51Cr-EDTA, Inulin und Thiosulfat beim Menschen. Klin Wochenschr 47: 415–420
Weidmann P, Beretta-Piccoli C, Meier A, Keusch G, Glück Z, Ziegler WH (1983) Antihypertensive mechanism of diuretic treatment with chlorthalidone. Complementary roles of the sympathetic axis and sodium. Kidney Int 23: 320–326
Cleaveland CR, Rangno RE, Shand DG (1972) A standardized isoproterenol sensitivity test. The effects of sinus arrhytmia, atropine and propranolol. Arch Int Med 130: 47–52
Grimm M, Weidmann P, Meier A, Keusch G, Ziegler W, Glück Z, Beretta-Piccoli C (1981) Correection of altered noradrenaline reactivity in essential hypertension by inadapamide. Br Heart J 46: 404–409
Weidmann P, Beretta-Piccoli C, Link L, Bianchetti MG, Boehringer K, Morton JJ (1983) Cardiovascular counterregulation during sympathetic inhibition in normal subjects and patients with mild essential hypertension. Hypertension 5: 873–880
Bianchetti MG, Weidmann P, Beretta-Piccoli C, Rupp U, Boehringer K, Link L, Ferrier C (1984) Disturbed noradrenergic blood pressure control in normotensive offspring of hypertensive families. Br Heart J 51: 306–311
Weidmann P, de Chatel R, Schiffmann A, Bachmann E, Beretta-Piccoli C, Ziegler WH, Vetter W and Reubi FC (1977) Interrelations among age and plasma renin, aldosterone and cortisol, urinary catecholamines and the body sodium/volume state in normal man. Klin Wochenschr 55: 725–733
Sealey JE, Gerten-Banes J, Laragh JH (1972) The renin system: Variations in man measured by radioimmunoassay or bioassay. Kidney Int 1: 240–253
Düsterdieck GO, McElwee G (1971) Estimation of angiotensin II concentration in human plasma by radioimmunoassay. Some applications to physiological and clinical states. Eur J Clin Invest 2: 32–38
Malvano R, Gandolfi C, Gianessi D, Giannotti P, Grosso P (1976) Radioimmunoassay of aldosterone in crude plasma extracts. J Nucl Biol Med 20: 37–44
Favre L, Glasson P, Riondel A, Vallotton MB (1983) Interaction of diuretics and non-steroidal anti-inflammatory drugs in man. Clin Sci 64: 407–415
Da Prada M, Zürcher G (1976) Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range. Life Sci 19: 1161–1174
Konzett H, Rothlin E (1953) Investigations on the hypotensive effect of the hydrogenated ergot alkaloids. Br J Clin Pharmacol 8: 201–207
Goldberg LI, Glock D, Kohli JD, Barnett A (1974) Separation of peripheral dopamine receptors by a selective DA1 antagonist. Hypertension 6 [Suppl 1]: I-25–I-30
Bianchetti MG, Beretta-Piccoli C, Weidmann P, Link L, Boehringer K, Ferrier C, Morton JJ (1983) Calcium and blood pressure regulation in normal and hypertensive subjects. Hypertension 5: II-57–II-65
Bianchetti MG, Beretta-Piccoli C, Weidmann P, Ferrier C, Link L, Gerber A (1984) Correction of cardiovascular hypersensitivity to norepinephrine by potassium supplementation in normotensive members of hypertensive families and patients with essential hypertension. J Hypertens 2 [Suppl 3]: 445–448
Weidmann P, Beretta-Piccoli C (1985) Pressor factors and cardiovascular pressor responsiveness in hypertension associated with non-azotemic diabetes mellitus. Hypertension (in press)
Barcroft H, Konzett H, Swan HJC (1951) Observations on the action of the hydrogenated alkaloids of the ergotoxine group on the circulation in man. J Physiol 112: 273–291
Ram CVS, Anderson RJ, Hart GR, Crumpler CP (1981) Alpha adrenergic blockade by prazosin in therapy of essential hypertension. Clin Pharmacol Ther 29: 719–722
Weil JV, Chidsey CA (1968) Plasma volume expansion resulting from interference with adrenergic function in normal man. Circulation 37: 54–61
Zanchetti AS (1977) Neural regulation of renin release. Experimental evidence and clinical implications in arterial hypertension. Circulation 56: 691–698
Ferrario CM, Gildenberg PL, McCubbin JW (1972) Cardiovascular effects of angiotensin mediated by the central nervous system. Circ Res 30: 257–262
Zimmerman BG, Gomer SK, Ciao Liao JI (1972) Action of angiotensin on vascular adrenergic nerve endings: Facilitation of norepinephrine release. Fed Proc 31: 1344–1350
Weidmann P, Hirsch D, Maxwell MH, Okun R and Schroth P (1974) Plasma renin and blood pressure during treatment with methyldopa. Am J Cardiol 34: 671–676
Flammer J, Weidmann P, Glück Z, Ziegler WH (1979) Cardiovascular and endocrine profile of adrenergic neurone blockade in normal and hypertensive man. Am J Med 66: 34–42
Hahn RA, McDonald BR (1984) Primate cardiovascular responses mediated by dopamine receptors: Effects of N,N-din-propyl-dopamine and LY171555. J Pharmacol Exp Ther 229: 132–138
Yamori Y (1977) Pathogenesis of spontaneous hypertension as a model for essential hypertension. Jpn Circ J 41: 259–266
Weidmann P, Keusch G, Flammer J, Ziegler WH, Reubi FC (1979) Increased ratio between changes in blood pressure and plasma norepinephrine in essential hypertension. J Clin Endocrinol Metab 48: 727–731
Goldstein DS (1983) Plasma catecholamines in essential hypertension. Hypertension 5: 86–99
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gerber, A., Weidmann, P. & Laederach, K. Cardiovascular regulation during administration of co-dergocrine to normal subjects. Eur J Clin Pharmacol 29, 565–572 (1986). https://doi.org/10.1007/BF00635894
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00635894